Trials / Recruiting
RecruitingNCT07215650
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of Cizutamig in Patients With Generalized Myasthenia Gravis (gMG)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Candid Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Generalized Myasthenia Gravis.
Detailed description
This is a Phase 1b, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of cizutamig in patients with Generalized Myasthenia Gravis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cizutamig | Cizutamig will be dosed according to the protocol |
Timeline
- Start date
- 2025-09-16
- Primary completion
- 2027-12-01
- Completion
- 2028-04-01
- First posted
- 2025-10-10
- Last updated
- 2025-11-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07215650. Inclusion in this directory is not an endorsement.